Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19

Summary

Recombinant human angotensin-converting enzyme 2 (rhACE2) as a treatment for patients with COVID-19 to block viral entry and decrease viral replication.

Timeline

Start

2020-04-30

Primary completion

2020-12-26

Completion

2020-12-26

Publications

• Chene A, Desrames A, Tomlinson A, Ruffie C, Tangy F, Gamain B. An ACE2-Based Bimodular Fusion Protein Enables Reorientation of Endogenous Anti-Epstein-Barr Virus Antibodies Toward SARS-CoV-2 Spike. J Infect Dis. 2023 Dec 20;228(12):1675-1679. doi: 10.1093/infdis/jiad329.
• Morrell ED. Tipping the Balance of Ubiquitination toward a Therapy for COVID-19. Am J Respir Cell Mol Biol. 2023 May;68(5):480-481. doi: 10.1165/rcmb.2023-0020ED. No abstract available.

Drugs

Indications